In a Pten-deleted prostate cancer mouse model, Camkk2 deletion or CAMKKβ pharmacological inhibition has been shown to suppress prostate tumorigenesis and reduce de novo lipogenesis, whereas Prkab1 (AMPK-β1) and Pten co-deletion accelerates tumor progression [210]. The gene discussed is PTEN; the disease is neoplasm.